Johnson & Johnson’s unique COVID-19 vaccine appeared to be safe and effective in studies, US. Food and Drug Administration (FDA) officials said in documents released on Wednesday, the path for emergency approval

The FDA’s independent panel of experts will meet on Friday to decide whether to approve the shot. While the panel is under no obligation to take the advice of its experts, the FDA did so when approving Pfizer-BioNTech vaccines and Moderna done

Johnson & Johnson’s vaccine prevented COVID-19 in a global study of nearly 44000 people 66 percent against multiple variants, the company said last month with

Its effectiveness ranged from 72 percent in the US to 66 percent in Latin America and 57 percent in South Africa, where a new variant has spread, although the vaccine was 85 percent effective overall in stopping severe cases of the disease

The vaccine was effective in reducing the risk of COVID-19 and preventing the polymerase chain reaction (PCR) test, which confirmed COVID-19 at least 14 days after vaccination, the FDA said in their briefing. p>

Three vaccine recipients had serious side effects in the study, but the FDA said their analysis did not raise any specific safety concerns that would preclude emergency approval

Johnson & Johnson had not previously released details of his clinical trial data beyond efficacy rates

While the overall efficacy numbers suggest the Johnson & Johnson candidate isn’t quite as strong as the two-dose competition, all COVID-19 vaccines around the world have been tested differently, making comparisons nearly impossible

It wouldn’t be surprising if one dose turned out to be slightly weaker than two doses, but policy makers will decide if this is an acceptable compromise to get more people vaccinated faster

The competing vaccines currently used in the US, Pfizer-BioNTech and ModernaS, Canada and many other countries must be kept frozen while the Johnson & Johnson shot can be kept in the refrigerator for three months, making it easier to use

Johnson & Johnson’s Pharmaceutical Division, Janssen, has applied for regulatory approval from Health Canada. This application is pending consideration

Canada has ordered 10 million cans from Johnson & Johnson, with options for up to 28 million more if needed. Most of these shots are expected to arrive in late September

A priority for CBC is to create a website that is accessible to all Canadians, including people with visual, hearing, motor, and cognitive problems

Johnson and Johnson Vaccine

World News – CA – Single-dose Johnson & Johnson vaccine is 66% effective, according to US Regulators | CBC news